CRIS - Curis, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.7500
-0.0200 (-1.13%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.7700
Open1.7800
Bid1.7000 x 800
Ask1.7500 x 3100
Day's Range1.7000 - 1.7956
52 Week Range0.6000 - 3.3300
Volume157,465
Avg. Volume643,493
Market Cap58.014M
Beta (3Y Monthly)1.28
PE Ratio (TTM)N/A
EPS (TTM)-0.9840
Earnings DateMay 1, 2019 - May 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
Trade prices are not sourced from all markets
  • Curis Regains Compliance with Nasdaq Continued Listing Requirements
    PR Newswire12 days ago

    Curis Regains Compliance with Nasdaq Continued Listing Requirements

    LEXINGTON, Mass., April 10, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced today that it received written confirmation from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market ("Nasdaq") notifying the Company that it has regained compliance with the minimum Market Value of Listed Securities ("MVLS") for continued listing on the Nasdaq Global Market. On December 27, 2018, the Company had received a letter from Nasdaq notifying it that it was not in compliance with the MVLS requirement set forth in Listing Rule 5450(b)(2)(A).

  • Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    PR Newswire17 days ago

    Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    LEXINGTON, Mass., April 5, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on April 2, 2019, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase 150,000 shares of Curis common stock to a new employee, with a grant date of April 2, 2019 (the "Q2 2019 Inducement Grant").

  • Thomson Reuters StreetEvents26 days ago

    Edited Transcript of CRIS earnings conference call or presentation 26-Mar-19 8:30pm GMT

    Q4 2018 Curis Inc Earnings Call

  • Associated Press27 days ago

    Curis: 4Q Earnings Snapshot

    The Lexington, Massachusetts-based company said it had a loss of 18 cents per share. The drug developer posted revenue of $2.8 million in the period. For the year, the company reported that its loss narrowed ...

  • Curis Reports Fourth Quarter and Year-End 2018 Financial Results
    PR Newswire27 days ago

    Curis Reports Fourth Quarter and Year-End 2018 Financial Results

    LEXINGTON, Mass., March 26, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the fourth quarter and year ended December 31, 2018. "2018 was a pivotal year for Curis as we transitioned from a company broadly engaged in discovery research and pipeline expansion into a company singularly focused on clinical execution," said James Dentzer, President and Chief Executive Officer of Curis. "As we move through 2019, we are focused on the development of first-in-class and best-in-class precision medicines that we hope will transform the lives of patients," he concluded.

  • Benzinga27 days ago

    The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 25) Axsome Therapeutics Inc (NASDAQ: AXSM ) Catalyst Pharmaceuticals ...

  • Benzinga28 days ago

    What's Driving The Rally In Microcap Biotech Curis?

    Thinly traded Curis, Inc. (NASDAQ: CRIS ) shares weremoving notably higher Monday on roughly 35 times their average volume. What Happened Curis announced Monday ahead of the market open that it reached ...

  • Biotech News: Why Curis Stock Is Soaring Today
    InvestorPlace28 days ago

    Biotech News: Why Curis Stock Is Soaring Today

    A recent bit of biotech news involving Curis has CRIS stock flying high on Monday.Source: Shutterstock Curis (NASDAQ:CRIS) has announced that it has reached a deal with Oberland Capital Management in connection to Erivedge. This has it offering selling rights for a portion of royalty revenues to the group for $135.70 million.According to Curis, the deal with Oberland Capital Management has it receiving a starting payment of $65.00 million. It is then able to collect additional payments of up to $70.70 million from the company. However, Erivedge must reach certain milestones for CRIS to receive these payments.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe biotech news also includes Curis already making good use of the money from the deal. It notes that it used a portion of the cash from the deal to pay off some of its debts. It is also using the remaining $30 million from the upfront payment to funds its operations."We believe this structure provides Curis with substantial non-dilutive capital today, while retaining significant participation in the future upside potential of Erivedge," James Dentzer, President and CEO of Curis, said in a statement. "The proceeds of this transaction further strengthen our cash position as we fund our three lead therapeutic candidates to reach their near term development catalysts and beyond." * 7 Marijuana Stocks to Play the CBD Trend Erivedge is a drug from Curis that is used to treat patients suffering from Hedgehog signaling due to genetic mutations. The drug does this by targeting a protein called Smoothened.CRIS stock was up 31% as of Monday morning and is up 74% since the start of the year. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dual-Class Stocks That Will Outperform * 7 Reasons Why Apple Streaming Won't Move the Needle for Apple Stock * 7 A-Rated Stocks to Buy in the Second Quarter As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Biotech News: Why Curis Stock Is Soaring Today appeared first on InvestorPlace.

  • MarketWatch28 days ago

    Curis' stock rockets on heavy volume after $135.7 million deal to sell portion of Erivedge royalties

    Shares of Curis Inc. rocketed 93% in very active premarket trade Monday, after the biotechnology company said it reached an agreement to sell a portion of royalties of its Erivedge cancer treatment for up to $135.7 million to funds managed by Oberland Capital Management LLC. Volume swelled to 1.8 million shares ahead of the open, compared with the full-day average of about 174,000 shares. Under terms of the deal, Curis received $65 million upfront, and is entitled to receive up to an additional $70.7 million in milestone payments if future royalties exceed pre-determined thresholds. In comparison, the company reported a third-quarter net loss of $7.22 million and revenue of $2.85 million. "We believe this structure provides Curis with substantial non-dilutive capital today, while retaining significant participation in the future upside potential of Erivedge," Curis Chief Executive James Dentzer said. "The proceeds of this transaction further strengthen our cash position as we fund our three lead therapeutic candidates to reach their near term development catalysts and beyond." Thes tock has tumbled 60% over the past 12 months through Friday, while the iShares Biotechnology ETF has tacked on 2.7% and the S&P 500 has gained 8.2%.

  • PR Newswire28 days ago

    Curis Sells Portion of Erivedge Royalties to Oberland Capital for up to $135.7 million

    LEXINGTON, Mass., March 25, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into an agreement with funds managed by Oberland Capital Management, LLC ("Oberland Capital") for up to $135.7 million in exchange for selling rights to a portion of royalty revenues on worldwide net sales of Erivedge. Under the terms of the agreement, Curis received $65.0 million in an upfront cash payment, plus Curis is entitled to receive up to an additional $70.7 million in milestone payments if future net royalties exceed pre-defined annual and cumulative thresholds.

  • PR Newswire28 days ago

    Curis to Release Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on March 26, 2019

    LEXINGTON, Mass., March 25, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its fourth quarter and full-year 2018 financial results on Tuesday, March 26, 2019, after the close of the US markets. Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, including fimepinostat, which is being investigated in clinical studies in patients with DLBCL and solid tumors. Curis is also engaged in a collaboration with Aurigene in the areas of immuno-oncology and precision oncology.

  • PR Newswire2 months ago

    Curis Announces Presentation at Cowen & Company 39th Annual Healthcare Conference

    LEXINGTON, Mass. , March 4, 2019 /PRNewswire/ --   Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced ...

  • PR Newswire3 months ago

    Curis, Inc. to Present at the 2019 BIO CEO & Investor Conference

    LEXINGTON, Mass. , Feb. 4, 2019 /PRNewswire/ --   Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced ...

  • Has Curis (CRIS) Outpaced Other Medical Stocks This Year?
    Zacks3 months ago

    Has Curis (CRIS) Outpaced Other Medical Stocks This Year?

    Is (CRIS) Outperforming Other Medical Stocks This Year?

  • PR Newswire3 months ago

    First Mesothelioma Patient Dosed in CA-170 Study

    LEXINGTON, Mass., Jan. 24, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the first mesothelioma patient has been enrolled and dosed in the Phase I study of CA-170. CA-170 is an orally available, dual inhibitor of VISTA and PDL1, which the company believes could provide benefit in tumors with high levels of VISTA expression. The company had previously announced its expectation to begin enrollment of mesothelioma patients in a dedicated cohort within the existing Phase 1 study.

  • First Eagle Investment Sells Stake in Curis Inc. at Steep Loss
    GuruFocus.com3 months ago

    First Eagle Investment Sells Stake in Curis Inc. at Steep Loss

    First Eagle Investment (Trades, Portfolio) Management axed 90.99% of its stake in Curis Inc. (CRIS) on Dec. 31 as the stock hovered near all-time low prices, the New York-based firm disclosed Wednesday. Warning! GuruFocus has detected 3 Warning Signs with CRIS.

  • Is Curis (CRIS) Outperforming Other Medical Stocks This Year?
    Zacks3 months ago

    Is Curis (CRIS) Outperforming Other Medical Stocks This Year?

    Is (CRIS) Outperforming Other Medical Stocks This Year?

  • Top 3 Healthcare Penny Stocks for 2018
    Investopedia3 months ago

    Top 3 Healthcare Penny Stocks for 2018

    These three healthcare penny stocks are poised for positive performance in the final quarter of 2018.

  • GlobeNewswire5 months ago

    Analysis: Positioning to Benefit within Dicerna Pharmaceuticals, Sun Life Financial, Autodesk, Eagle Pharmaceuticals, Curis, and Accenture — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 30, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • PR Newswire5 months ago

    Curis to Present at the 60th Annual Meeting of the American Society of Hematology

    LEXINGTON, Mass. , Nov. 20, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, ...

  • PR Newswire5 months ago

    Curis to Present at 33rd Society for Immunotherapy of Cancer Annual Meeting and Cowen IO NEXT Summit

    LEXINGTON, Mass. , Nov. 7, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, ...

  • Thomson Reuters StreetEvents6 months ago

    Edited Transcript of CRIS earnings conference call or presentation 1-Nov-18 12:30pm GMT

    Q3 2018 Curis Inc Earnings Call

  • Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates
    Zacks6 months ago

    Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates

    Curis (CRIS) delivered earnings and revenue surprises of 29.03% and 19.62%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press6 months ago

    Curis: 3Q Earnings Snapshot

    On a per-share basis, the Lexington, Massachusetts-based company said it had a loss of 22 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...